1 active not recruiting. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Active not recruiting 1 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Ibrutinib - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin | Phase 4 | Active not recruiting | Pharmacyclics Switzerland GmbH | 297 | 2017-05-22 | 2025-10-30 |
Graft vs Host Disease (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1)
Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
ibrutinib (1)
Pharmacyclics Switzerland GmbH (1)
Australia (1) · Canada (1) · Czechia (1) · France (1) · Hungary (1) · Italy (1) · New Zealand (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Sweden (1) · Taiwan (1) · Turkey (Türkiye) (1) · Ukraine (1)
Kevin Wu (1)
2016 (1)